Compare Strategy Inc. (MSTR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs TG Therapeutics Inc — how do they compare? Strategy Inc. trades at $154.34 (market cap $60.40B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Strategy Inc. is far larger — about 7.4× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Strategy Inc. for 112 Days and TG Therapeutics Inc for 16 Days on average.
| MSTR | TGTX | |
|---|---|---|
Market Cap | $60.40B | $8.16B |
Volume | 23,421,830 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $315.47 | $59.06 |
52-Week Low | $82.31 | $26.94 |
Typical Hold Time | 112 Days | 16 Days |
Enterprise Value | $79.16B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $151.47, down 1.24% on the day, with a bullish technical signal and strong analyst support. The stock shows significant volatility with recent earnings misses but maintains a 62% buy rating from analysts who see substantial upside to the $253.36 consensus target. Recent news highlights Citigroup doubling its price target to $240 amid Bitcoin-related momentum, though the company faces fundamental challenges with negative net income margins and substantial debt levels.
The outlook remains polarized between technical optimism and fundamental concerns. While analyst sentiment and Bitcoin exposure provide potential catalysts, investors face risks from persistent losses, high valuation multiples, and balance sheet leverage. The stock's performance remains heavily tied to external cryptocurrency markets rather than organic business growth.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
